London, September 23, 2024

Arthur D. Little (ADL) announced the appointment of Robert Albarano as a Partner in its Healthcare and Life Sciences (HCLS) practice, growing its North American team. Based in ADL’s New York office, Robert is an experienced Phama strategy consultant with over 20 years success in business development and projects across the life sciences product lifecycle. This includes covering all major therapeutic areas, especially in the area of Pricing and Market Access. In his new role Robert will focus on supporting the growth of ADL’s North American HCLS practice.

Rob joins ADL from specialist healthcare consultancy Trinity Life Sciences, where he has been a Managing Director since 2021. During his career, he has led major projects around critical business issues for life sciences organizations and private equity providers. Prior to working at Trinity Life Sciences, Rob was a Partner at Triangle Insights Group and L.E.K. Consulting. He also previously worked at IQVIA and Monitor Deloitte. 

Craig Wylie, Managing Partner at ADL, comments, “Robert is an acknowledged expert in the critical business challenges currently facing life sciences and private equity companies, especially around pricing, commercial, corporate and go-to-market strategies. Adding his skills and experience to our existing capabilities will strengthen our successful HCLS practice and enable us to grow as the U.S. market continues its expansion.”

Robert Albarano, Partner at ADL, adds, “The U.S. healthcare sector is changing rapidly, leading to a growing need for commercial strategy consulting to help companies realize their portfolio’s full potential. ADL already has a strong healthcare and life sciences practice, and I’m excited to join the team, contributing my understanding and experience to help clients successfully navigate a fast-changing policy, customer and financing environment.”

Robert holds an MBA from The University of Chicago Booth School of Business and an MA in Economics from Ohio University.